Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 16c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.42 -0.18%
Revenue Growth %: +24.1%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.13, $0.16 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $49.14 million versus the consensus estimate of $49.44 million.
GUIDANCE:
Vanda reiterates 2018 net product sales guidance of $180 million to $200 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Freeport-McMoRan shares surge as copper hits record $14,694/ton
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
